Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2025)

Upstream Bio (UPB) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $391.2 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 68.11% year-over-year to $391.2 million; the TTM value through Sep 2025 reached $1.7 billion, up 400.03%, while the annual FY2024 figure was $481.7 million, 311.03% up from the prior year.
  • Liabilities and Shareholders Equity reached $391.2 million in Q3 2025 per UPB's latest filing, down from $420.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $481.7 million in Q4 2024 and bottomed at $117.2 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $349.9 million, with a median of $405.9 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 311.03% in 2024, then soared 68.11% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $117.2 million in 2023, then skyrocketed by 311.03% to $481.7 million in 2024, then fell by 18.79% to $391.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $391.2 million in Q3 2025, $420.5 million in Q2 2025, and $456.2 million in Q1 2025.